<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052623</url>
  </required_header>
  <id_info>
    <org_study_id>FRA.GHAT.2009</org_study_id>
    <nct_id>NCT01052623</nct_id>
  </id_info>
  <brief_title>Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)</brief_title>
  <acronym>GHAT</acronym>
  <official_title>Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the status of the growth hormone/ insulin-like growth factor-1
      (GH/IGF-1) axis in relation to growth failure, body weight and composition and
      neuroprotection in children with Ataxia telangiectasia (AT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growth failure and GH/IgF-1 deficiency has been described in patients diagnosed with Ataxia
      telangiectasia (AT) [Boder et al.,1958]. This condition is a fatal inherited disease caused
      by a mutation of the ATM gene on chromosome 11 leading to chromosomal instability,
      immunodeficiency, cancer susceptibility and and endocrinological abnormalities. In this
      regard, several groups demonstrated a cross-linking of ATM with growth factor pathways.
      Participation of the ATM protein in insulin signaling through phosphorylation of
      eIF-4E-binding protein 1 has been postulated [Yang et al.,2000]. Peretz et al.[2001]
      described that expression of the insulin-like growth factor-I receptor is (IGF-I R) ATM
      dependent in a pathway regulating radiation response. In addition, Shahrabani-Gargir et
      al.[2004] found that the ATM gene controls IGF-I R gene expression in a DNA damage response
      pathway. Suzuki et al.[2004] described that IGF-I phosphorylates AMPK-alpha, a key regulator
      of cholesterol and fatty acid synthesis, acts in an ATM-dependent manner . We have recently
      demonstrated reduced levels of circulating Insulin-like growth factor-I (IGF-I) and its main
      binding protein 3 (IGFBP-3) in AT patients accompanied with decreased body mass index
      [Schubert et al.,2005]. Furthermore, apart from regulating somatic growth and metabolism,
      evidence suggests that the GH/IGF-I axis is involved in the regulation of brain growth,
      development and myelination. Moreover, GH and particularly IGF-1 have potential
      neuroprotective effects in different in vitro and in vivo experimental models. In addition we
      have recently shown that extracerebellar MRI-lesions in AT go along with deficiency of the
      GH/IGF-1 Axis, markedly reduced body weight, high ataxia scores and advanced age [Kieslich et
      al.,2009]. Supplementation with these growth hormones might overcome the progressive
      dystrophy and may have clinical benefits against the progression of neurodegeneration and
      immunodeficiency.

      We found that supplementation with GH significantly increased longevity of Atm-deficient mice
      and improve T-cell immunity and locomotor behaviour [Schubert et al.,2009]. Surprisingly
      IGF-1 was not generated in the ATM deficient mice, indicating that the GH/IGF-1 signalling is
      impaired. Taken this into account a accurate diagnostic approach of the GH/IGF-1 axis is
      mandatory including a IGF-1 generation test before long term treatment either with GH or
      IGF-1 is justified in humans.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the GH increase after Arginine Provocation Test</measure>
    <time_frame>at minute 0, 30, 60, 90 und 120 after infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The GH increase after Clonidine Provocation Test. To evaluate the safety and efficacy of the IGF-1 generation test. To correlate GH/IgF-1 deficiency to BMI To correlate GH/IgF-1 deficiency to MRI findings</measure>
    <time_frame>at minute 0, 30, 60, 90 und 120 after dosing of Clonidin. IgF-1 generation test after 5 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ataxia Telangiectasia</condition>
  <condition>Growth Failure</condition>
  <arm_group>
    <arm_group_label>Growth hormone-testing (GH/IGF-1-testing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.
The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate</intervention_name>
    <description>1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).</description>
    <arm_group_label>Growth hormone-testing (GH/IGF-1-testing)</arm_group_label>
    <other_name>Catapressan</other_name>
    <other_name>Growth hormone</other_name>
    <other_name>NutropinAq</other_name>
    <other_name>Progynova 21 mite</other_name>
    <other_name>L-Arginin_hydrochlorid-einmolar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of AT

          -  Have no fusion of epiphyses/closed growth plates as determined by X-ray of left wrist
             and hand (special skeletal age film)

          -  Be between 3 years to 18 years old and have not completed puberty

          -  Consent to permit blood and/or tissue samples for storage

          -  Demonstrate growth failure: height below the 10th percentile for chronological age

          -  Have a primary care physician at home

          -  Demonstrate growth failure, defined as growth velocity (measured as linear growth)
             that is less than 5% to 10% of that expected for children of the same age group, over
             the past 12 months

          -  Willingness to remain hospitalized for several days

          -  Provide evidence of serum IGF-1 level performed within the preceding 6 months and the
             results fall below 25% range of normal limits for age

        Exclusion Criteria:

          -  Have fusion of epiphyseal plates

          -  Be under the age of 3 years or have reached completion of puberty

          -  Have a serum IGF-1 level that is above the 25% range of normal limits for age

          -  Be above the 10th percentile height for chronological age

          -  Demonstrate any history of anaphylactic reaction or hypersensitivity to one of the GH
             formulation

          -  Have any active or suspected neoplasia

          -  Demonstrate signs of intracranial hypertension as evidenced by papilledema upon
             examination by fundoscopy

          -  Have any condition that, in the investigator's opinion, places the patient at undue
             risk by participating in the study

          -  Be unwilling to undergo testing or procedures associated with this protocol

          -  Have acute or chronic infections

          -  Have a hypersensitivity to one of the drugs: Clonidine hydrochlorid, Arginine
             hydrochlorid, Estradiol valerate, Somatropin

          -  Have a presence of bradycardia, cardiac arrhythmia, have symptoms of a sick sinus
             syndrome

          -  Suffer from depression

          -  Have acute or recurrent thrombosis

          -  Have acute liver diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ChildrenÂ´s Hospital, Goethe-University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Zielen, Prof. Dr.</last_name>
    <phone>0049-69-6301-83063</phone>
    <email>Stefan.Zielen@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralf Schubert, Dr.</last_name>
    <phone>0049-69-6301-83611</phone>
    <email>Ralf.Schubert@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital, Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Zielen, Prof. Dr.</last_name>
      <phone>0049-69-6301-83063</phone>
      <email>Stefan.Zielen@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Ralf Schubert, Dr.</last_name>
      <phone>0049-69-6301-83611</phone>
      <email>Ralf.Schubert@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Zielen, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Dresel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franziska Hoche, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Christman, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.info-at.de</url>
  </link>
  <reference>
    <citation>BODER E, SEDGWICK RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958 Apr;21(4):526-54.</citation>
    <PMID>13542097</PMID>
  </reference>
  <reference>
    <citation>Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008 Oct;9(10):759-69. doi: 10.1038/nrm2514. Review. Erratum in: Nat Rev Mol Cell Biol. 2008 Dec;9(12). doi: 10.1038/nrm2514.</citation>
    <PMID>18813293</PMID>
  </reference>
  <reference>
    <citation>Schubert R, Reichenbach J, Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol. 2005 Jun;140(3):517-9.</citation>
    <PMID>15932513</PMID>
  </reference>
  <reference>
    <citation>Isgaard J, Aberg D, Nilsson M. Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol. 2007 Jun;32(2):103-13. Review.</citation>
    <PMID>17557036</PMID>
  </reference>
  <reference>
    <citation>Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000 Dec;2(12):893-8.</citation>
    <PMID>11146653</PMID>
  </reference>
  <reference>
    <citation>Peretz S, Jensen R, Baserga R, Glazer PM. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1676-81. Epub 2001 Feb 6.</citation>
    <PMID>11172010</PMID>
  </reference>
  <reference>
    <citation>Shahrabani-Gargir L, Pandita TK, Werner H. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology. 2004 Dec;145(12):5679-87. Epub 2004 Sep 2.</citation>
    <PMID>15345673</PMID>
  </reference>
  <reference>
    <citation>Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H. IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun. 2004 Nov 19;324(3):986-92.</citation>
    <PMID>15485651</PMID>
  </reference>
  <reference>
    <citation>Kieslich M, Hoche F, Reichenbach J, Weidauer S, Porto L, Vlaho S, Schubert R, Zielen S. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum. 2010 Jun;9(2):190-7. doi: 10.1007/s12311-009-0138-0.</citation>
    <PMID>19898915</PMID>
  </reference>
  <reference>
    <citation>Schubert R, Schmitz N, Pietzner J, Tandi C, Theisen A, Dresel R, Christmann M, Zielen S. Growth hormone supplementation increased latency to tumourigenesis in Atm-deficient mice. Growth Factors. 2009 Oct;27(5):265-73. doi: 10.1080/08977190903112663.</citation>
    <PMID>19626507</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>July 2, 2010</last_update_submitted>
  <last_update_submitted_qc>July 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Stefan Zielen</name_title>
    <organization>Johann Wolfgang Goethe University Hospitals</organization>
  </responsible_party>
  <keyword>GH/IGF-1</keyword>
  <keyword>Ataxia telangiectasia (AT)</keyword>
  <keyword>IGF-1 Generation Test</keyword>
  <keyword>Growth hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

